Arcutis Biotherapeutics Inc ((ARQT)) has held its Q2 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Arcutis Biotherapeutics’ latest earnings call struck a decidedly upbeat tone, with management stressing strong commercial momentum, rising profitability, and expanded regulatory wins around its flagship dermatology drug ZORYVE. While executives acknowledged higher operating costs and some execution risks, they argued that accelerating demand and pipeline breadth leave the company well positioned for continued growth.

Revenue Surge Underscores Demand Momentum

Arcutis reported net product revenues of $129.9 million for Q2 2026, a 59% year-over-year increase and 23% sequential growth versus Q1 2026. Management framed the performance as evidence that ZORYVE is gaining traction across multiple dermatology indications, driving a step-up in top-line scale even as market access dynamics remain complex.

Upgraded Outlook Signals Confidence in Trajectory

Reflecting the strong quarter, the company raised its full-year 2026 net revenue guidance to a range of $525 million to $540 million from $480 million to $495 million previously. The roughly 9% midpoint uplift highlights management’s confidence that recent commercial initiatives can sustain double-digit growth into the second half of the year.

Return to Profitability and Solid Cash Generation

Arcutis posted Q2 2026 net income of $15.0 million, a sharp swing from the $15.9 million net loss recorded in Q2 2025, supported by scaling revenues and disciplined R&D spending. Operating cash flow was positive at $12.6 million, and the company ended the quarter with $238.9 million in cash and marketable securities, providing ample liquidity.

Prescription Growth and Share Gains in Key Class

Demand reached a new high with more than 280,000 prescriptions written in the quarter across indications and formulations, underscoring uptake among dermatologists and other prescribers. Management estimates that ZORYVE now holds roughly 50% share of the branded topical nonsteroidal class, suggesting it is becoming a category leader.

Pediatric Approval and sNDA Acceptance Expand Reach

Regulatory momentum remained a central highlight as the FDA approved ZORYVE cream 0.3% for plaque psoriasis in children aged two and above in June 2026. In addition, the agency accepted a supplemental application for ZORYVE cream 0.05% in mild-to-moderate atopic dermatitis in infants from three months of age, further broadening the potential patient base.

New Channels and Access Tools Aim to Deepen Penetration

To support growth, Arcutis launched a virtual health platform offering tele-dermatology with integrated insurance and fulfillment support, and partnered with an AI-enabled prescription workflow solution to reduce friction after prescriptions are written. The company also completed its dermatology salesforce expansion and added a targeted PCP and pediatrics team to reach more prescribers.

Pipeline Advancing Across Multiple Dermatology Indications

Beyond ZORYVE’s current labels, the pipeline is moving forward with a Phase 2 vitiligo proof-of-concept study fully enrolled and a readout expected in Q4 2026, and a Phase 2 hidradenitis suppurativa trial targeting results in Q1 2027. Arcutis also initiated programs in pruritus, nail psoriasis, and PD-1/PD-L1-associated skin events, while biologic candidate ARQ-34 progresses through early clinical stages.

Patent Additions Bolster Long-Term ZORYVE Protection

The company announced two new patents covering formulation and method-of-use, lifting the ZORYVE portfolio to 28 patents overall, which management emphasized as Orange Book listable. With exclusivity timelines stretching to around 2037 for the cream and 2042 for the foam, Arcutis underscored the durability of its intellectual property around its core asset.

Operating Costs Climb with Commercial Scale-Up

SG&A expenses rose to $82.1 million in Q2 2026 from $69.2 million in the prior-year quarter, a 19% increase driven mainly by personnel and salesforce expansion as the company invests to capture share. Cost of sales also increased to $10.9 million from $7.5 million, roughly 45% higher, reflecting the higher volumes moving through the channel.

Gross-to-Net Remains a Drag on Margins

Despite the strong revenue growth, management noted that gross-to-net rates remained in the 50s during the quarter, tempering near-term margin expansion. Executives guided only moderate improvement to the low-50s range by year-end, signaling that rebates and access programs will continue to weigh on realized pricing even as volumes rise.

Clinical and Execution Risks Temper the Growth Story

Key pipeline programs such as ARQ-34 remain in early stages, with proof-of-concept readouts in vitiligo and hidradenitis suppurativa carrying typical clinical risk that could affect future expansion plans. Management also acknowledged that newly launched telehealth and AI access platforms are still in early rollout, with conversion rates and pricing dynamics yet to be proven.

Debt and Leadership Changes in Focus for Investors

Arcutis reported total debt of $101.9 million, which appears manageable in light of its cash position and positive operating cash flow but remains an item to track as reinvestment continues. The resignation of Chief Commercial Officer Todd Edwards and appointment of an interim successor introduce a degree of leadership transition risk, though management emphasized continuity.

R&D Spending Stable as Portfolio Mix Shifts

Research and development expenses were relatively flat at $20.4 million versus $19.5 million a year earlier, reflecting a modest 4.6% increase amid shifting trial costs and new clinical and medical affairs investments. The steady spend signals ongoing commitment to broadening the dermatology franchise while balancing profitability goals.

Guidance Points to Continued Growth and Positive Cash Flow

For the full year 2026, Arcutis now expects net revenue between $525 million and $540 million, backed by Q2’s $129.9 million in product sales, strong prescription trends, and a gross-to-net rate stabilizing in the 50s but modestly improving. Management anticipates continued quarter-over-quarter net sales growth in Q3 and Q4, supported by salesforce expansion, direct-to-consumer efforts, telehealth initiatives, and sustained positive operating cash flow.

Arcutis’ earnings call painted a picture of a dermatology specialist entering a more mature commercial phase, with ZORYVE driving strong growth and a return to profitability while multiple pipeline and access initiatives position the company for further expansion. Investors will be watching how management navigates margin pressures, execution risks, and leadership changes, but the overall trajectory remains firmly positive.